Related Experiment Videos
Use of 99mTc-bicisate in activation studies by split-dose technique
S Holm1, P L Madsen, B Sperling
1Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Summary
This study assessed the test-retest reliability of 99mTc-bicisate (ethyl cysteinate dimer) brain SPECT imaging. Results indicate fair day-to-day reproducibility, suggesting its utility in visual activation studies.
Area of Science:
- Neuroimaging
- Radiochemistry
Background:
- Single Photon Emission Computed Tomography (SPECT) is a crucial neuroimaging technique.
- 99mTc-bicisate (ethyl cysteinate dimer) is a SPECT tracer used for brain perfusion studies.
- Assessing the reliability of SPECT tracers in test-retest scenarios is vital for clinical and research applications.
Purpose of the Study:
- To evaluate the test-retest properties of the SPECT tracer 99mTc-bicisate.
- To investigate the tracer's performance in short-interval, split-dose studies under resting and visual stimulation conditions.
- To determine the day-to-day reproducibility of 99mTc-bicisate SPECT.
Main Methods:
- Utilized fast dynamic SPECT (Tomomatic 232) with eight slices.
- Employed a split-dose protocol over two days with twelve volunteers.
- Applied visual activation using a flickering chessboard pattern and analyzed data in predefined regions of interest (ROIs).
Main Results:
- Day-to-day reproducibility was found to be fair, with minimal significant changes in most ROIs.
- A regional difference in observed tracer washout was noted, ranging from 7.9% to 11.5% in cortical ROIs.
- The inferior frontal cortex showed a small, significant 2% decrease in reproducibility.
Conclusions:
- 99mTc-bicisate demonstrates fair test-retest reproducibility for brain SPECT imaging.
- The tracer is suitable for short-interval, split-dose studies, including those involving visual stimulation.
- Further research can leverage these findings for robust neuroimaging research and clinical diagnostics.